Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $3.13 billion. The enterprise value is $2.09 billion.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 79.72 million shares outstanding. The number of shares has increased by 29.31% in one year.
| Current Share Class | 79.72M |
| Shares Outstanding | 79.72M |
| Shares Change (YoY) | +29.31% |
| Shares Change (QoQ) | +11.45% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 87.49% |
| Float | 66.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.80, with a Debt / Equity ratio of 0.03.
| Current Ratio | 16.80 |
| Quick Ratio | 16.17 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -63.41 |
Financial Efficiency
Return on equity (ROE) is -27.92% and return on invested capital (ROIC) is -19.13%.
| Return on Equity (ROE) | -27.92% |
| Return on Assets (ROA) | -18.52% |
| Return on Invested Capital (ROIC) | -19.13% |
| Return on Capital Employed (ROCE) | -27.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.28M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +89.32% in the last 52 weeks. The beta is -0.13, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | +89.32% |
| 50-Day Moving Average | 41.24 |
| 200-Day Moving Average | 34.65 |
| Relative Strength Index (RSI) | 46.62 |
| Average Volume (20 Days) | 1,253,848 |
Short Selling Information
The latest short interest is 6.78 million, so 8.51% of the outstanding shares have been sold short.
| Short Interest | 6.78M |
| Short Previous Month | 6.31M |
| Short % of Shares Out | 8.51% |
| Short % of Float | 10.19% |
| Short Ratio (days to cover) | 5.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -306.35M |
| Pretax Income | -204.18M |
| Net Income | -269.44M |
| EBITDA | -306.33M |
| EBIT | -306.35M |
| Earnings Per Share (EPS) | -$3.74 |
Full Income StatementBalance Sheet
The company has $686.29 million in cash and $36.23 million in debt, giving a net cash position of $1.09 billion or $13.70 per share.
| Cash & Cash Equivalents | 686.29M |
| Total Debt | 36.23M |
| Net Cash | 1.09B |
| Net Cash Per Share | $13.70 |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 13.60 |
| Working Capital | 670.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$262.63 million and capital expenditures -$999,000, giving a free cash flow of -$263.63 million.
| Operating Cash Flow | -262.63M |
| Capital Expenditures | -999,000 |
| Free Cash Flow | -263.63M |
| FCF Per Share | -$3.31 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |